In support of this idea, combination of LAIR-1 inhibition with a TGF-β trap control agent that blocks TGF-β but lacks binding to PD-L1 did elicit increased tumor infiltration of CD8+ T cells and NK cells, although it was to a lesser degree than that observed with the combination NC410 plus bintrafusp alfa. The gene discussed is LAIR1; the disease is neoplasm.